Xponance Inc. Sells 671 Shares of Novo Nordisk A/S (NYSE:NVO)

Xponance Inc. lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 24.6% in the fourth quarter, Holdings Channel reports. The firm owned 2,057 shares of the company’s stock after selling 671 shares during the period. Xponance Inc.’s holdings in Novo Nordisk A/S were worth $213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in NVO. Jennison Associates LLC lifted its position in shares of Novo Nordisk A/S by 100.3% during the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after buying an additional 11,727,507 shares during the last quarter. Polen Capital Management LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at $718,995,000. FMR LLC lifted its position in shares of Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after buying an additional 6,654,614 shares during the last quarter. Morgan Stanley lifted its holdings in Novo Nordisk A/S by 96.5% during the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after purchasing an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after purchasing an additional 4,350,862 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $126.85 on Monday. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $569.24 billion, a PE ratio of 46.89, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. The business’s 50-day moving average price is $126.86 and its 200-day moving average price is $112.21. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. UBS Group assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.